This analysis examines the historical and forecast performance for Amgen in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Amgen's performance against key rivals in the ethical pharmaceutical sector See how Amgen will suffer as a consequence of recent safety warnings concerning Aranesp and Epogen restricting their sales growth Evaluate the impact Phase III musculoskeletal product denosumab will have on the company's growth.